| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Leal M et al. | Antibody-drug conjugates: an emerging modality for the treatment of cancer. | 2014 | Ann. N. Y. Acad. Sci. | pmid:25123209 |
| Prota AE et al. | A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. | 2014 | Proc. Natl. Acad. Sci. U.S.A. | pmid:25114240 |
| Bender B et al. | A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. | 2014 | AAPS J | pmid:24917179 |
| Cretella D et al. | Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. | 2014 | Mol. Cancer | pmid:24898067 |
| English DP et al. | T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. | 2014 | Cancer Med | pmid:24890382 |
| Perez EA et al. | Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. | 2014 | Breast Cancer Res. | pmid:24887458 |
| Barok M et al. | Trastuzumab emtansine: mechanisms of action and drug resistance. | 2014 | Breast Cancer Res. | pmid:24887180 |
| Tripathy D et al. | The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2014 | BMC Cancer | pmid:24885258 |
| Amiri-Kordestani L et al. | FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. | 2014 | Clin. Cancer Res. | pmid:24879797 |
| Giordano SH et al. | Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. | 2014 | J. Clin. Oncol. | pmid:24799465 |
| White C | NICE confirms advanced breast cancer drug is too expensive for NHS. | 2014 | BMJ | pmid:25106642 |
| Corrigan PA et al. | Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. | 2014 | Ann Pharmacother | pmid:25082874 |
| Diéras V et al. | Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. | 2014 | J. Clin. Oncol. | pmid:25024070 |
| Yu L et al. | Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. | 2014 | Int. J. Gynecol. Cancer | pmid:24987913 |
| Lambert JM and Chari RV | Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. | 2014 | J. Med. Chem. | pmid:24967516 |
| Sibaud V et al. | Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. | 2014 | Breast Cancer Res. Treat. | pmid:24929675 |
| Martin K et al. | The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. | 2014 | Cancer Immunol. Immunother. | pmid:24906866 |
| Kim MT et al. | Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. | 2014 | Bioconjug. Chem. | pmid:24873191 |
| Kolarich AR et al. | Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage. | 2014 | Acta Oncol | pmid:24834794 |
| Boku N | HER2-positive gastric cancer. | 2014 | Gastric Cancer | pmid:23563986 |